Perspective Therapeutics has dosed the first patient in a new cohort of its Phase 1/2a trial evaluating VMT01 in combination with Bristol Myers Squibb's nivolumab (Opdivo) for melanoma patients with positive MC1R imaging scans.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.